Home' Australian Pharmacist : Australian Pharmacist August 2015 Contents ADVERTORIAL
Breathlessness in COPD
One of the cardinal symptoms of chronic obstructive pulmonary disease (COPD) is breathlessness, also known as dyspnoea, which is
a major cause of disability and anxiety associated with the disease.
Patients who are breathless may experience limitations in routine
daily activities, such as walking to the shops or keeping pace with their peers.2
Unfortunately, some patients with COPD who are treated with long-acting bronchodilator monotherapy continue to suffer significant symptoms
such as breathlessness and poor quality of life.
Anoro Ellipta may provide a combination therapy option for some of these patients.
What is Anoro Ellipta?
Anoro Ellipta is a long-term, once-daily
treatment for COPD that combines two
24-hour bronchodilators with different yet
complementary modes of action:4
• Umeclidinium (UMEC) 62.5mcg –
a long-acting muscarinic antagonist
(LAMA) inhibits muscarinic receptors in
the lung, reducing the contraction of
airway smooth muscle and producing
• Vilanterol (VI) 25mcg – a long-acting
-agonist (LABA) that exerts its
bronchodilatory effect by stimulating
-adrenergic receptors in airway
Who should take Anoro Ellipta?
Anoro Ellipta is indicated as a long-term
once daily maintenance bronchodilator
treatment to relieve symptoms in adult
patients with COPD.
COPD-X recommendations include dual
bronchodilator (LAMA/LABA) therapy for
regular use in patients who have persistent
troublesome breathlessness, if maintenance
monotherapy is not adequate.
What can pharmacists do to
support patients who have been
prescribed Anoro Ellipta?
Pharmacists play an important role under
the Quality Use of Medicines (QUM)
principles by ensuring that patients who
have been prescribed Anoro Ellipta take
the right dose and are able to use their
• Anoro Ellipta should be taken once
• Anoro Ellipta is a dry powder inhaler
(DPI) that comes pre-filled and ready
No need for patients to
• Anoro Ellipta has been shown to be
an easy-to-use device8,9 with 3 main
steps: open, inhale, close.
pharmacists should still always check
that customers can correctly use their
inhalation device. For full device use
instructions, please refer to Anoro
Ellipta Product Information.
What benefits may Anoro Ellipta
provide to appropriate COPD
Anoro Ellipta provides a number of efficacy
benefits for appropriate breathless patients
• Compared to monotherapy with tiotropium,
it provides a significantly improved trough
FEV1 at Day 169 in moderate to very severe
COPD patients (p<0.001).
• It has also been shown to significantly
reduce breathlessness compared to
placebo, as measured by Transition
Dyspnoea Index focal score (p≤0.001).
• In addition, there is evidence that exercise
endurance time (EET) may be improved
with Anoro Ellipta: In one study EET
significantly improved by 69.4 seconds
(p=0.003) compared to placebo, but a
second study did not show a significant
improvement over placebo (21.9 seconds,
In clinical studies, Anoro Ellipta was
well tolerated.6 -8 Common side effects
include cough, nasopharyngitis,
upper respiratory infection.
Pharmacy update: Treating
COPD with Anoro Ellipta
REFERENCES: 1. Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global Strategy for the Diagnosis, Management and Prevention of COPD 2015. 2 . Jones PW et al. Respir Med 2011; 105: 57–66.
3. Dransfield MT et al. Prim Care Respir J 2011; 20: 46–53 . 4. Anoro Ellipta Approved Product Information (v2.0). 5 . Abramson M et al. COPD-X Concise Guide for Primary Care. Brisbane. Lung Foundation Australia. 2014.
6. Maleki-Yazdi MR et al. Respir Med 2014; 108(12): 1752–60 . 7 . Donohue JF et al. Respir Med 2013; 107: 1538–46. 8 . Maltais F et al. Ther Adv Respir Dis 2014; 8(6): 169–81. 9 . Riley JH et al. Use of a new dry powder inhaler to
deliver umeclidinium/vilanterol in the treatment of COPD. (P4145) Poster presented at ERS, Sept 2013.
For information on GSK products or to report an adverse event involving a GSK product, please contact GSK Medical Information on 1800 033 109. Anoro and
Ellipta are registered trade marks of the GSK group of companies. Anoro Ellipta was developed in collaboration with Theravance, Inc. GlaxoSmithKline Australia
Pty Ltd. ABN 47 100 162 481. Melbourne, VIC. AUS/UCV/0029/15b; Date of approval July 2015. AM5786A.
Please review the primary advertisement for PBS and Product Information before prescribing.
Links Archive Australian Pharmacist July 2015 Australian Pharmacist September 2015 Navigation Previous Page Next Page